在 iTTP 的老年患者中使用卡普拉西祖马布治疗:西班牙TTP注册表的经验
Inés Gómez-Seguí1, Joan Cid2, Miquel Lozano2
1Department of Hematology and Hemotherapy La Fe University and Polytechnic Hospital Valencia Spain.
HemaSphere
|April 17, 2025
概括
卡普拉西祖马布在老年人中有效治疗免疫血栓性血栓性缺血性紫外线 (iTTP),与年轻患者的疗效相似. 然而,老年iTTP患者面临更高的出血风险,需要在治疗期间密切监测.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫血栓性血栓性缺血性紫外线 (iTTP) 主要影响中年人,但老年患者也可能受到影响.
- 卡普拉西祖马布是对iTTP的批准治疗方法,但其在老年人群中的安全性和有效性仍未得到充分研究.
研究的目的:
- 评估60岁及以上 iTTP 患者用卡普拉西祖马布治疗的管理和结果.
- 为了比较卡普拉西祖马布在老年iTTP患者和年轻患者的安全性和疗效.
主要方法:
- 来自西班牙TTP注册表的iTTP患者的分析,他们在急性发作期间接受了caplacizumab.
- 60岁以上 (n=29) 和60岁以下 (n=70) 的患者之间的结局比较.
主要成果:
- 老年患者患有更高的出血事件发生率导致卡普拉西祖马布中止 (17%对1%,p=0.008).
- 在老年患者中,卡普拉西祖马布在降低折射性和死亡 (3%) 和恶化 (10%) 的效果上表现出相似的效果.
- 在一位老年患者中,严重出血促使卡普拉西祖马布的启动延迟.
结论:
- 卡普拉西祖马布似乎有效治疗老年患者的iTTP,结果与年轻人相似.
- 老年iTTP患者的出血风险增加需要仔细监测和进一步研究如何管理血栓和出血风险.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...